What Explains China's Biotech Rise? Genomics, Data, and the Global Biotech Ecosystem

Why is China’s biotech industry advancing so quickly? I talk with Abigail Coplin of Vassar College to unpack China’s biotech strategy, BGI, genomics, AI-driven drug discovery, gene therapies, biotech regulation, and what the U.S.-China biotech race means for innovation, national security, and the future of medicine.Why has China emerged so quickly as a global biotech powerhouse?What gives Chinese biotech companies an edge over their Western competitors?How did BGI become one of the world’s most influential genomics companies?Why are China’s gene and cell therapies advancing so rapidly?What should U.S. policymakers know about China's biotech industry?Links:Abigail’s academic profileAbigail’s policy paper for the Penn Project on the Future of U.S.-China Relations: “Getting Biotechnology Right: Managing Risk and Reward Between the U.S. and China in the Life Sciences”Yu Zhou and Abigail Coplin. 2022. “Innovation in a Science-Based Sector: The Institutional Evolution behind China’s Emerging Biopharmaceutical Innovation Boom.” The China Review.For transcripts and more information, check out the High Capacity newsletter.Follow host Kyle Chan on Twitter / X.